|
1
|
Kuznik A, Pazdzierniok-Holewa A, Jewula P
and Kuznik N: Bisphosphonates-much more than only drugs for bone
diseases. Eur J Pharmacol. 866(172773)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kates SL and Ackert-Bicknell CL: How do
bisphosphonates affect fracture healing? Injury. 47 (Suppl
1):S65–68. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rosini S, Rosini S, Bertoldi I and
Frediani B: Understanding bisphosphonates and osteonecrosis of the
jaw: Uses and risks. Eur Rev Med Pharmacol Sci. 19:3309–3317.
2015.PubMed/NCBI
|
|
4
|
Maines E, Monti E, Doro F, Morandi G,
Cavarzere P and Antoniazzi F: Children and adolescents treated with
neridronate for osteogenesis imperfecta show no evidence of any
osteonecrosis of the jaw. J Bone Miner Metab. 30:434–438.
2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Himelstein AL, Foster JC, Khatcheressian
JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS,
O'Connor T, et al: Effect of longer-interval vs standard dosing of
zoledronic acid on skeletal events in patients with bone
metastases: A randomized clinical trial. JAMA. 317:48–58.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Street J, Bao M, deGuzman L, Bunting S,
Peale FV Jr, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL,
Daugherty A, et al: Vascular endothelial growth factor stimulates
bone repair by promoting angiogenesis and bone turnover. Proc Natl
Acad Sci USA. 99:9656–9661. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jacobsen KA, Al-Aql ZS, Wan C, Fitch JL,
Stapleton SN, Mason ZD, Cole RM, Gilbert SR, Clemens TL, Morgan EF,
et al: Bone formation during distraction osteogenesis is dependent
on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res. 23:596–609.
2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Behr B, Leucht P, Longaker MT and Quarto
N: Fgf-9 is required for angiogenesis and osteogenesis in long bone
repair. Proc Natl Acad Sci USA. 107:11853–11858. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Emad B, Sherif EM, Basma GM, Wong RW,
Bendeus M and Rabie AB: Vascular endothelial growth factor augments
the healing of demineralized bone matrix grafts. Int J Surg.
4:160–166. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
van Cann T, Loyson T, Verbiest A, Clement
PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C,
Vandeweyer RO, et al: Incidence of medication-related osteonecrosis
of the jaw in patients treated with both bone resorption inhibitors
and vascular endothelial growth factor receptor tyrosine kinase
inhibitors. Support Care Cancer. 26:869–878. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tan YY, Yang YQ, Chai L, Wong RW and Rabie
AB: Effects of vascular endothelial growth factor (VEGF) on
MC3T3-E1. Orthod Craniofac Res. 13:223–228. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ganesan K, Bansal P, Goyal A and Roane D:
Bisphosphonate. In: StatPearls [Internet]. StatPearls Publishing,
Treasure Island, FL, 2021.
|
|
14
|
Gupta M and Gupta N: Bisphosphonate
Related Jaw Osteonecrosis. In: StatPearls [Internet]. StatPearls
Publishing, Treasure Island, FL, 2020.
|
|
15
|
Dhillon S: Zoledronic acid (Reclas
®, Aclasta ®): A review in osteoporosis.
Drugs. 76:1683–1697. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhu W, Xu R, Du J, Fu Y, Li S, Zhang P,
Liu L and Jiang H: Zoledronic acid promotes TLR-4-mediated M1
macrophage polarization in bisphosphonate-related osteonecrosis of
the jaw. FASEB J. 33:5208–5219. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Endo Y, Kumamoto H, Nakamura M, Sugawara
S, Takano-Yamamoto T, Sasaki K and Takahashi T: Underlying
mechanisms and therapeutic strategies for bisphosphonate-related
osteonecrosis of the jaw (BRONJ). Biol Pharm Bull. 40:739–750.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Limones A, Saez-Alcaide LM, Diaz-Parreño
SA, Helm A, Bornstein MM and Molinero-Mourelle P:
Medication-related osteonecrosis of the jaws (MRONJ) in cancer
patients treated with denosumab VS. zoledronic acid: A systematic
review and meta-analysis. Med Oral Patol Oral Cir Bucal.
25:e326–e336. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huja SS, Fernandez SA, Phillips C and Li
Y: Zoledronic acid decreases bone formation without causing
osteocyte death in mice. Arch Oral Biol. 54:851–856.
2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Pozzi S, Vallet S, Mukherjee S, Cirstea D,
Vaghela N, Santo L, Rosen E, Ikeda H, Okawa Y, Kiziltepe T, et al:
High-dose zoledronic acid impacts bone remodeling with effects on
osteoblastic lineage and bone mechanical properties. Clin Cancer
Res. 15:5829–5839. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Huang X, Huang S, Guo F, Xu F, Cheng P, Ye
Y, Dong Y, Xiang W and Chen A: Dose-dependent inhibitory effects of
zoledronic acid on osteoblast viability and function in
vitro. Mol Med Rep. 13:613–622. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hu K and Olsen BR: The roles of vascular
endothelial growth factor in bone repair and regeneration. Bone.
91:30–38. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Vincenzi B, Napolitano A, Zoccoli A,
Iuliani M, Pantano F, Papapietro N, Denaro V, Santini D and Tonini
G: Serum VEGF levels as predictive marker of bisphosphonate-related
osteonecrosis of the jaw. J Hematol Oncol. 5(56)2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Street J and Lenehan B: Vascular
endothelial growth factor regulates osteoblast survival-evidence
for an autocrine feedback mechanism. J Orthop Surg Res.
4(19)2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li L, Liu F, Huang W, Wang J, Wan Y, Li M,
Pang Y and Yin Z: Ricolinostat (ACY-1215) inhibits VEGF expression
via PI3K/AKT pathway and promotes apoptosis in osteoarthritic
osteoblasts. Biomed Pharmacother. 118(109357)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hu K and Olsen BR: Osteoblast-derived VEGF
regulates osteoblast differentiation and bone formation during bone
repair. J Clin Invest. 126:509–526. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Clark D, Wang X, Chang S,
Czajka-Jakubowska A, Clarkson BH and Liu J: VEGF promotes
osteogenic differentiation of ASCs on ordered fluorapatite
surfaces. J Biomed Mater Res A. 103:639–645. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang Q, Yu W, Lee S, Xu Q, Naji A and Le
AD: Bisphosphonate induces osteonecrosis of the jaw in diabetic
mice via NLRP3/caspase-1-dependent IL-1β mechanism. J Bone Miner
Res. 30:2300–2312. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chen ZH, Jin SH, Wang MY, Jin XL, Lv C,
Deng YF and Wang JL: Enhanced NLRP3, caspase-1, and IL-1β levels in
degenerate human intervertebral disc and their association with the
grades of disc degeneration. Anat Rec (Hoboken). 298:720–726.
2015.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Yang L, Liu J, Shan Q, Geng G and Shao P:
High glucose inhibits proliferation and differentiation of
osteoblast in alveolar bone by inducing pyroptosis. Biochem Biophys
Res Commun. 522:471–478. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhao H, Huang H, Alam A, Chen Q, Suen KC,
Cui J, Sun Q, Ologunde R, Zhang W, Lian Q and Ma D: VEGF mitigates
histone-induced pyroptosis in the remote liver injury associated
with renal allograft ischemia-reperfusion injury in rats. Am J
Transplant. 18:1890–1903. 2018.PubMed/NCBI View Article : Google Scholar
|
